Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X

Hao, Yue; Xu, Manyi; Zhou, Huan; Si, Jinfei; Fang, Yu; Xu, C.; Song, Zhengbo

doi:10.1007/s12032-022-01895-6

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study with a small sample size of 15 NSCLC patients with exon 18 E709X or E709 T710delinsX mutations, all of whom received treatment with afatinib ( n = 11) or third-generation EGFR-TKIs ( n = 4), failed to find a statistically significant distinction between the two when it came to the median PFS (13.5 vs. 10.9 months, p = 0.774). The study found that individuals with NSCLC who had these particular mutations might profit from afatinib or third-generation EGFR-TKI therapy, despite the study’s small number of participants [ 18 ]. The E709_T710delinsD mutation is considered the most commonly occurring deletion mutation in exon 18, and, although rare, isolated case reports imply that afatinib could be a useful therapeutic choice.…”

Section: Afatinib’s Effectiveness In Curing Various Uncommon Egfr Mut...mentioning

confidence: 99%

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Afatinib, the world’s first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with an EGFR-sensitive mutation or for patients with locally advanced or metastatic squamous lung cancer whose disease progresses during or after platinum-containing chemotherapy. Currently, with the use of third-generation EGFR-TKIs, afatinib is no longer clinically indicated as the first choice for patients with NSCLC who have EGFR-sensitive mutations. However, afatinib showed a considerable inhibitory effect in NSCLC patients with uncommon EGFR mutations (G719X, S768I, and L861Q) according to a combined post hoc analysis of the LUX-Lung2/3/6 trials. With the development of genetic testing technology, the detection rate of uncommon EGFR mutations is increasing. The aim of this paper is to describe in detail the sensitivity of rare EGFR mutations to afatinib and to provide information and a reference for those suffering from advanced NSCLC who have uncommon EGFR mutations.

show abstract

Section: Afatinib’s Effectiveness In Curing Various Uncommon Egfr Mut...mentioning

confidence: 99%